Jürgen Bajorath
Jürgen Bajorath has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Peter S. Linsley
Bristol-Myers Squibb Pharmaceutical Research Institute, 3005 First Avenue, Seattle, Washington 98121, USA; Tel: (206) 727-3612; Fax: (206) 727-3602
4 shared publicationsAlejandro Aruffo
Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121
2 shared publicationsHans D. Ochs
Department of Pediatrics, University of Washington, Seattle, Washington 98195
1 shared publicationKuniaki Seyama
Department of Pediatrics, University of Washington, Seattle, Washington 98195
1 shared publicationLinda Harris
Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121, USA
1 shared publicationMichael A. Bowen
Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121
1 shared publication
Latest Publications
- 31 May 1997
- Published by Springer Nature in Journal of Molecular Modeling
- Vol. 3 (5) , 216-223
A Molecular Model of CD86 and Analysis of Mutations which Disrupt Receptor Binding
- 31 May 1997
- Published by Springer Nature in Journal of Molecular Modeling
- Vol. 3 (5) , 216-223
A Molecular Model of CD86 and Analysis of Mutations which Disrupt Receptor Binding
- 21 February 1997
- Published by Springer Nature in Journal of Molecular Modeling
- Vol. 3 (2) , 117-123
Molecular Modeling of Immunoglobulin Superfamily Proteins: Predicting the Three Dimensional Structure of the Extracellular Domain of CTLA-4 (CD152)
- 21 February 1997
- Published by Springer Nature in Journal of Molecular Modeling
- Vol. 3 (2) , 117-123
Molecular Modeling of Immunoglobulin Superfamily Proteins: Predicting the Three Dimensional Structure of the Extracellular Domain of CTLA-4 (CD152)
- Open Access
- 1 March 1996
- Published by Wiley in Protein Science
- Vol. 5 (3) , 531-534
Classification of mutations in the human CD40 ligand, gp39, that are associated with X‐linked hyper IgM syndrome
The interaction between the T cell activation antigen gp39 and CD40, its receptor CD40 on B cells, plays a critical role in the regulation of humoral immune responses. Using a detailed three‐dimensional model of the gp39 extracellular region, we have analyzed 20 mutations in gp39 that were, with one exception, isolated from patients with X‐linked hyper IgM (XHIM) syndrome. On the basis of this analysis, the mutations were classified according to their predicted locations and effects. Twelve mutations are thought to compromise the gp39 structure by affecting interactions in hydrophobic core regions or at monomer interfaces, whereas seven others map closely to gp39 residues important for interaction with CD40. The latter mutations may thus, directly or indirectly, interfere with CD40 binding. One naturally occurring mutant whose carrier displays normal immune responses maps to a solvent‐exposed position in a loop region of the molecule.
- 1 March 1996
- Published by Wiley in Protein Science
- Vol. 5 (3) , 531-534
Open AccessClassification of mutations in the human CD40 ligand, gp39, that are associated with X‐linked hyper IgM syndrome
The interaction between the T cell activation antigen gp39 and CD40, its receptor CD40 on B cells, plays a critical role in the regulation of humoral immune responses. Using a detailed three‐dimensional model of the gp39 extracellular region, we have analyzed 20 mutations in gp39 that were, with one exception, isolated from patients with X‐linked hyper IgM (XHIM) syndrome. On the basis of this analysis, the mutations were classified according to their predicted locations and effects. Twelve mutations are thought to compromise the gp39 structure by affecting interactions in hydrophobic core regions or at monomer interfaces, whereas seven others map closely to gp39 residues important for interaction with CD40. The latter mutations may thus, directly or indirectly, interfere with CD40 binding. One naturally occurring mutant whose carrier displays normal immune responses maps to a solvent‐exposed position in a loop region of the molecule.
- Open Access
- 1 August 1995
- Published by Wiley in Protein Science
- Vol. 4 (8) , 1644-1647
Molecular model of the N‐terminal receptor‐binding domain of the human CD6 ligand ALCAM
CD6-ligand interactions have been implicated in the regulation of T-cell adhesion and activation. CD6 is a member of the scavenger receptor family, whereas its human ligand (ALCAM) belongs to the immunoglobulin superfamily. The extracellular region of ALCAM includes five immunoglobulin-like domains. As a fusion protein, the N-terminal extracellular domain of ALCAM (ALCAMD1) binds specifically to CD6. We report the construction, assessment, and analysis of a molecular model of ALCAMD1. The model defines the CDR-analogous loops, the location of N-linked glycosylation sites, and residues that form the β-sheet faces of the immunoglobulin-like domain. Predicted structural characteristics of the A'GFCC “C” face of the model are consistent with the presence of monomeric and dimeric forms of ALCAMD1, which has implications for the receptor-ligand interactions.
- 1 August 1995
- Published by Wiley in Protein Science
- Vol. 4 (8) , 1644-1647
Open AccessMolecular model of the N‐terminal receptor‐binding domain of the human CD6 ligand ALCAM
CD6-ligand interactions have been implicated in the regulation of T-cell adhesion and activation. CD6 is a member of the scavenger receptor family, whereas its human ligand (ALCAM) belongs to the immunoglobulin superfamily. The extracellular region of ALCAM includes five immunoglobulin-like domains. As a fusion protein, the N-terminal extracellular domain of ALCAM (ALCAMD1) binds specifically to CD6. We report the construction, assessment, and analysis of a molecular model of ALCAMD1. The model defines the CDR-analogous loops, the location of N-linked glycosylation sites, and residues that form the β-sheet faces of the immunoglobulin-like domain. Predicted structural characteristics of the A'GFCC “C” face of the model are consistent with the presence of monomeric and dimeric forms of ALCAMD1, which has implications for the receptor-ligand interactions.
- 1 February 1995
- Published by Wiley in Protein Science
- Vol. 4 (2) , 306-310
Profiles for the analysis of immunoglobulin sequences: Comparison of V gene subgroups
A format for the structure‐oriented analysis of immunoglobulin (Ig) variable region sequences is presented and applied to generate sequence profiles for comparison of heavy‐ and light‐chain subgroups. The profile allows simultaneous evaluation of sequences and structural information and can be used for a number of different applications.
- 1 February 1995
- Published by Wiley in Protein Science
- Vol. 4 (2) , 306-310
Profiles for the analysis of immunoglobulin sequences: Comparison of V gene subgroups
A format for the structure‐oriented analysis of immunoglobulin (Ig) variable region sequences is presented and applied to generate sequence profiles for comparison of heavy‐ and light‐chain subgroups. The profile allows simultaneous evaluation of sequences and structural information and can be used for a number of different applications.
- Open Access
- 1 November 1994
- Published by Wiley in Protein Science
- Vol. 3 (11) , 2148-2150
Immunoglobulin fold characteristics of B7–1 (CD80) and B7–2 (CD86)
B7–1 and B7–2 are expressed on antigen‐presenting cells and bind to the CD28 and CTLA‐4 receptors on T cells. These interactions trigger a costimulatory pathway that is essential for T‐cell activation. B7–1 and B7–2 are members of the immunoglobulin superfamily (IgSF) and, despite sharing common function, have only limited sequence similarity. The B7–1 extracellular region was previously subdivided into 2 IgSF domains, an N‐terminal V(ariable)‐like domain, followed by a C(onstant)‐like domain. We recently reported that the V‐like domains of B7–1 and B7–2 share some significant sequence similarities with 3 major histocompatibility complex (MHC)‐encoded members of the IgSF. We have now applied inverse folding methodology to assess the compatibility of the B7–1 and B7–2 extracellular region sequences with currently available 3‐dimensional structures. In these calculations, the sequences of the N‐terminal (V‐like) domains in B7–1 and B7–2 were not compatible with known structures, including the IgSF V‐set. In contrast, the sequences of the C‐like domains were compatible with IgSF C‐set structures and were best recognized by the β2‐microglobulin (β2m) domain of MHC Class I. A sequence comparison of the C‐like domains in the B7 molecules showed that 11 of 17 rigorously conserved residues in B7–1 and B7–2 are not IgSF C‐1 set consensus residues. When mapped onto the corresponding positions of the β2m structure, the conserved residues in B7 cluster on the surface, where they may interact with the B7 V‐like domain or other molecules.
- 1 November 1994
- Published by Wiley in Protein Science
- Vol. 3 (11) , 2148-2150
Open AccessImmunoglobulin fold characteristics of B7–1 (CD80) and B7–2 (CD86)
B7–1 and B7–2 are expressed on antigen‐presenting cells and bind to the CD28 and CTLA‐4 receptors on T cells. These interactions trigger a costimulatory pathway that is essential for T‐cell activation. B7–1 and B7–2 are members of the immunoglobulin superfamily (IgSF) and, despite sharing common function, have only limited sequence similarity. The B7–1 extracellular region was previously subdivided into 2 IgSF domains, an N‐terminal V(ariable)‐like domain, followed by a C(onstant)‐like domain. We recently reported that the V‐like domains of B7–1 and B7–2 share some significant sequence similarities with 3 major histocompatibility complex (MHC)‐encoded members of the IgSF. We have now applied inverse folding methodology to assess the compatibility of the B7–1 and B7–2 extracellular region sequences with currently available 3‐dimensional structures. In these calculations, the sequences of the N‐terminal (V‐like) domains in B7–1 and B7–2 were not compatible with known structures, including the IgSF V‐set. In contrast, the sequences of the C‐like domains were compatible with IgSF C‐set structures and were best recognized by the β2‐microglobulin (β2m) domain of MHC Class I. A sequence comparison of the C‐like domains in the B7 molecules showed that 11 of 17 rigorously conserved residues in B7–1 and B7–2 are not IgSF C‐1 set consensus residues. When mapped onto the corresponding positions of the β2m structure, the conserved residues in B7 cluster on the surface, where they may interact with the B7 V‐like domain or other molecules.
- Open Access
- 1 August 1994
- Published by Wiley in Protein Science
- Vol. 3 (8) , 1341-1343
Extending the B7 (CD80) gene family
B7‐1 and B7‐2 are members of the immunoglobulin superfamily (IgSF) and important regulators of T cell‐mediated immune responses. Despite sharing only limited sequence identity, B7‐1 and B7‐2 bind common receptors, CD28 and CTLA‐4, on T cells and have similar functional properties. We have found that the extracellular V(ariable)‐like domains of B7‐1 and B7‐2 share significant sequence similarities with 3 major histocompatibility complex (MHC)‐encoded members of the IgSF: butyrophilin, myelin/oligodendrocyte glycoprotein, and the chicken MHC molecule, B‐G. This raises the question whether there is an evolutionary link between the MHC, which encodes molecules regulating the antigen specificity of T lymphocyte responses, and B7 molecules, which co‐stimulate these responses in antigen‐nonspecific fashion.
- 1 August 1994
- Published by Wiley in Protein Science
- Vol. 3 (8) , 1341-1343
Open AccessExtending the B7 (CD80) gene family
B7‐1 and B7‐2 are members of the immunoglobulin superfamily (IgSF) and important regulators of T cell‐mediated immune responses. Despite sharing only limited sequence identity, B7‐1 and B7‐2 bind common receptors, CD28 and CTLA‐4, on T cells and have similar functional properties. We have found that the extracellular V(ariable)‐like domains of B7‐1 and B7‐2 share significant sequence similarities with 3 major histocompatibility complex (MHC)‐encoded members of the IgSF: butyrophilin, myelin/oligodendrocyte glycoprotein, and the chicken MHC molecule, B‐G. This raises the question whether there is an evolutionary link between the MHC, which encodes molecules regulating the antigen specificity of T lymphocyte responses, and B7 molecules, which co‐stimulate these responses in antigen‐nonspecific fashion.